Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ripoll, L.
Right arrow Articles by Lagrange, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ripoll, L.
Right arrow Articles by Lagrange, P. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1996) 37, 987-991
© 1996 The British Society for Antimicrobial Chemotherapy

brief-report

Interaction of macrolides with adornase during DNA hydrolysis

Laurent Ripolla, Philippe Reinertb, Louis-Ferdinand Pépinc and Philippe H. Lagrangea

aLaboratoire de Microbiologie, Hôpital Saint-Louis I avenue Claude Vellefaux, 75010 Paris, France bService de Pediatrie, Centre Hospitalier Inter communal 40 avenue de Verdun, 94010 Creteil, France c Pfizer, 86 rue de Paris, 91407 Orsay, France

Received 3 July 1995; returned 30 October 1995; accepted 11 January 1996

Since patients with cystic fibrosis are often treated with adornase to reduce sputum viscosity, and because of preliminary reports of efficacy of long-term low-dose erythromycin therapy in chronic airway diseases, it is likely that adornase and macrolides might be given together in such patients. A possible interaction between these drugs was therefore investigated. Using hyperchromic effect to quantify adornase activity, a time- and dose-dependent inhibitory effect on human DNA hydrolysis has been observed for erythromycin, roxithromycin and azithromycin. Inhibitory doses 50% for adornase were graphically determined. Azithromycin exhibited the strongest inhibitory effect.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Respir JHome page
K.W. Southern and P.M. Barker
Azithromycin for cystic fibrosis
Eur. Respir. J., November 1, 2004; 24(5): 834 - 838.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. K. Rubin and M. O. Henke
Immunomodulatory Activity and Effectiveness of Macrolides in Chronic Airway Disease
Chest, February 1, 2004; 125 (2009): 70S - 78S.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.